Avrobio Inc., a clinical-stage gene therapy company, completed a review of its business, including the status of its programs, resources, and capabilities. Avrobio has decided to halt further development of its programs and conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value.

As part of this evaluation process, Avrobio will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction.

In a statement, the company said that there can be no assurance that its exploration will result in Avrobio pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms, if at all. Avrobio has not set a timetable for completion of this evaluation process and does not intend to disclose further developments unless and until it is determined that further disclosure is appropriate or necessary.